0 item(s)
View cart
You have no items in your shopping cart.
02
Oct
Organoids have transformed lung research, but most lack one key feature of real tissue: blood vessels. Vascularized organoids address this by including endothelial cells alongside the tissue's own lineages.
This article reviews the main vascularization strategies and walks through how vascularized lung organoids are made from human iPSCs.
Article Table of Contents
Why organoids need blood vessels
Most organoids lack a vascular network. As they grow, the core can become hypoxic, and important interactions between epithelium and endothelium are missing. In the lung, where gas exchange depends on close contact between alveolar epithelium and capillaries, this is a significant gap. Vascularized organoids aim to include endothelial cells that develop alongside the tissue's own cells.
Approaches to vascularizing organoids
| Approach | How it works | Trade-offs |
|---|---|---|
| Co-culture | Add endothelial cells (e.g., HUVEC) to organoids | Simple, but endothelial cells are not developmentally matched |
| Transplantation | Implant organoids into a host animal to recruit vessels | Robust vessels, but requires animals |
| Microfluidic devices | Grow organoids on chips with perfused channels | Enables flow; specialized equipment |
| Co-differentiation | Direct iPSCs to generate epithelial and endothelial lineages together | Developmentally matched; protocol-dependent |
Vascularized lung organoids from iPSCs
In the co-differentiation approach, human iPSCs are aggregated into embryoid bodies and guided through mesendoderm and a vascularized primitive gut stage before being matured into lung organoids. The resulting organoids can show branching structures and early alveolus-like regions, with lung lineage markers such as NKX2.1, SPC and KRT5 alongside vascular markers.
- Lung development: branching morphogenesis and early alveolar development in a human system.
- Disease modeling: fibrosis, injury and infection models involving the epithelial–vascular interface.
- Respiratory virus research: human lung tissue models with relevant cell types.
- Drug and toxicity testing: 3D models that include a vascular compartment.
Workflow at a glance
- Day −1: form embryoid bodies from single iPSCs in ultra-low-attachment U-bottom plates.
- Day 0–3: mesendoderm induction with daily medium changes.
- Day 3–7: vascularized primitive gut stage.
- Day 7: transfer to a basement membrane matrix-coated Transwell insert.
- Day 10 onward: lung organoid maturation, typically to Day 26–30+.
The Biofargo iPSC-Derived Vascularized Lung Organoid Differentiation Kit provides six chemically defined, stage-specific media for this workflow and supports 48 organoids per kit. Start from healthy iPSCs maintained in hESC/iPSC expansion medium. For adult tissue-derived lung models, see the Mouse Lung Organoid Medium Kit.
Shop the Products in This Article
|
iPSC-Derived Vascularized Lung Organoid Differentiation Kit Cat. No. BFIVASLUNGKIT · 1 kit (48 organoids) |
Shop Now |
|
hESC/iPSC Adherent Expansion Medium Kit (High-Protein) Cat. No. BFIPSCM500 · 500 mL |
Shop Now |
|
Mouse Lung Organoid Medium Kit Cat. No. BFMLUNGO100 · 100 mL kit |
Shop Now |
Explore the Vascularized Lung Organoid Differentiation Kit →
Questions about organoid or differentiation workflows? Email contact@biofargo.com.
